Tesamorelin safety, side effects and monitoring
Tesamorelin is a GHRH analogue and — importantly — one of the few peptides in this category that is <b>genuinely FDA-approved</b>, though for a narrow indication: the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It is marketed as Egrifta. Everything else it is sold for is off-label.
Safety profile
Injection-site reactions, joint pain, muscle pain, peripheral oedema and — significantly — glucose intolerance. Tesamorelin can worsen blood-sugar control, which matters a great deal in a population that overlaps with metabolic disease. It is contraindicated in active malignancy, pituitary disorders and pregnancy. Fasting glucose and HbA1c should be monitored.
Monitoring
A legitimate programme establishes a baseline before it ships anything. For Tesamorelin, ask what will be measured before you start, at what interval it will be re-measured, and what result would indicate the treatment is not working — a provider who cannot answer the last question has no plan for stopping.
Questions to ask
- Am I receiving FDA-approved Egrifta, or a compounded preparation? They are not the same thing.
- Do I actually have the indication it is approved for?
- How will my blood glucose and HbA1c be monitored?
- What is the evidence for my specific goal, as opposed to the approved one?
- What happens when I stop?
Questions to ask about the pharmacy
The pharmacy matters more than the telehealth brand on the front of the website. The telehealth company arranges the consultation; the pharmacy makes the medicine you inject.
- Which specific pharmacy will fill my prescription? Not "our network" — the name of the facility.
- Is it a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility? These are different regulatory categories with different oversight, and a company can use both for different products.
- In which state is it licensed, and can I look up the licence? State boards of pharmacy publish licensee databases.
- What is the exact salt form and concentration? Semaglutide sodium and semaglutide acetate are not the same active ingredient as the semaglutide base in approved products, and the FDA has said they are not appropriate for compounding.
- Is the vial single-dose or multi-dose? A multi-dose vial requires you to measure each dose yourself, which is the most common source of the dosing errors behind reported adverse events.
- Will you provide a certificate of analysis?
- Has the pharmacy received any FDA warning letter or state board action?
A provider that answers all seven in writing is demonstrating something real. A provider that will not name its pharmacy has given you an answer, whether it intended to or not.
Frequently asked questions
What does Tesamorelin cost through telehealth?
We have not verified a price and will not publish one we cannot substantiate. This page gives you the method to evaluate any quote you are given.
Is Tesamorelin FDA-approved?
Tesamorelin (Egrifta) is FDA-approved, for one specific indication: excess visceral abdominal fat in HIV-infected patients with lipodystrophy. This is the strongest regulatory position of any peptide on this site, and it deserves to be stated clearly.
It also deserv
Does Tesamorelin work?
The approval rests on real randomised trial data showing a meaningful reduction in visceral adipose tissue in the HIV-lipodystrophy population, with associated improvements in triglycerides. That evidence is good.
It is also specific. There is no comparable trial evide
Sources
- U.S. Food and Drug Administration — approved labels and compounding guidance for this molecule.
- PubMed / NIH — indexed human clinical literature.
- ClinicalTrials.gov — registered trials, where they exist.
- Our source hierarchy and pricing-verification methodology.
Percentage of participants reporting each event. Gastrointestinal effects dominate and are most pronounced during dose escalation. Source: SURMOUNT-1, N Engl J Med 2022.
Safety, contraindications and monitoring
Tirzepatide carries a boxed warning for thyroid C-cell tumours, based on rodent data. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. This is not a precaution to weigh; it is a hard stop.
Serious but less common risks include pancreatitis, gallbladder disease (cholelithiasis and cholecystitis), acute kidney injury secondary to dehydration from vomiting or diarrhoea, diabetic retinopathy complications in people with existing retinopathy, and hypoglycaemia when combined with insulin or a sulfonylurea. Severe abdominal pain radiating to the back warrants urgent assessment for pancreatitis, not a message to a chat widget.
Before starting, a clinician should establish a baseline: weight and BMI, blood pressure, HbA1c or fasting glucose, a lipid panel, and renal and hepatic function. During treatment, tolerance should be reviewed at each escalation step rather than escalated automatically on a calendar.
Percentage of participants reporting each event. Gastrointestinal effects dominate, are usually mild-to-moderate, and are most pronounced during dose escalation. Source: SURMOUNT-1, N Engl J Med 2022.
Questions to ask your clinician
- Given my history — specifically thyroid, pancreatic and gallbladder — is a GLP-1 appropriate for me at all?
- What baseline laboratory work will you order before I start?
- What is my target dose, and how quickly will we escalate?
- Which side effects should make me call you rather than wait it out?
- What is the plan for maintenance, and what happens if I stop?
- Will I see the same clinician at each follow-up, or a different one each time?
Dosing, titration, and what it does to your bill
| Period | Dose | What it is for |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Tolerance-building only. This dose is not intended to produce weight loss. If your provider's price is quoted at 2.5 mg, that is not the price of treatment. |
| Weeks 5–8 | 5 mg | First therapeutic dose (−15.0% in SURMOUNT-1). |
| Weeks 9–12 | 7.5 mg | Escalate only if tolerated. |
| Weeks 13–16 | 10 mg | A common maintenance dose (−19.5%). |
| Weeks 17–20 | 12.5 mg | Escalate only if tolerated. |
| Week 21+ | 15 mg | Maximum maintenance dose (−20.9%). |
The advertised price is usually the 2.5 mg price. On a programme that escalates with dose, the rate you are quoted at signup is for a dose the label explicitly describes as a starting dose — not a treatment dose. Ask what you will pay at 10 mg, and compare that number instead.
A 'microdose' of ~1 mg/week sits below every dose in SURMOUNT. The trials used 5, 10 and 15 mg. A microdose is not a discounted route to the SURMOUNT result; it is a different product with a smaller expected effect and no equivalent trial evidence.
Discontinuation: what the withdrawal trial found
Aronne LJ et al., JAMA 2024, n=670 (NCT04660643). After a 36-week open-label lead-in, participants randomised to placebo regained ~14% of body weight over the following 52 weeks; those who continued lost a further ~5%. This is the single most important trial for understanding the true cost of treatment.
In SURMOUNT-4 — the randomised withdrawal trial — participants taken off tirzepatide after a 36-week lead-in regained roughly 14% of body weight over the following year, while those who continued lost a further ~5%. This is the trial that most changes the arithmetic of treatment, and it is almost never cited on a pricing page.
The consequence is financial as much as clinical. If holding the result requires holding the medication, then the figure that matters is not the introductory price, and not even the annual price. It is the indefinite monthly price. Anyone selecting a provider on the strength of a first-month rate is optimising the wrong variable entirely.
Compounded, brand, microdose, ODT — four different products
These words are used interchangeably in marketing and they are not interchangeable at all. The distinction decides what evidence applies to what you are actually buying.
| Product | Regulatory status | Trial evidence |
|---|---|---|
| Brand Zepbound / Mounjaro (injection) | FDA-approved. Reviewed for safety, effectiveness and quality before marketing. | Direct. SURMOUNT and SURPASS tested exactly this product. |
| Brand Foundayo (oral, orforglipron) | FDA-approved. Its own trial programme. | Direct, for that product. |
| Compounded Semaglutide (injection, full dose) | NOT FDA-approved. No premarket review of safety, effectiveness or quality. | None for the compounded product itself. Same molecule, same route — but the product in your hand was never in a trial. |
| Microdose (~1 mg/wk) | NOT FDA-approved. | None. Sits BELOW every dose in SURMOUNT (5/10/15 mg). Expect a smaller effect. |
| ODT / oral compounded | NOT FDA-approved. | NONE. No trial has ever tested it. Oral bioavailability for these peptides is a real pharmacological problem and is unpublished for this product. |
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.
The regulatory reality every provider glosses over
| Date | What happened | Why it matters to you |
|---|---|---|
| 15 Dec 2022 | Tirzepatide added to the FDA drug shortage list. | The shortage exception opens. This is what created the compounded market. |
| 2 Oct 2024 | FDA declares the tirzepatide shortage RESOLVED. | The legal basis for compounding tirzepatide as an 'essentially a copy' drug begins to close. |
| 19 Dec 2024 | FDA reaffirms resolution in a declaratory order. | Sets a 60-day (503A) and 90-day (503B) transition. |
| 18 Feb 2025 | 503A enforcement discretion for tirzepatide ENDS. | State-licensed pharmacies must stop compounding tirzepatide copies. |
| 19 Mar 2025 | 503B enforcement discretion for tirzepatide ENDS. | Outsourcing facilities must stop too. |
| 24 Apr / 7 May 2025 | Courts deny the Outsourcing Facilities Association injunction. | OFA v. FDA, N.D. Tex. The FDA's determination stands. |
| 30 Apr 2026 | FDA proposes excluding tirzepatide, semaglutide and liraglutide from the 503B bulks list. | Finding: no clinical need. Comment period closed 29 Jun 2026. |
The rule that governs everything: “essentially a copy”
Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act bar compounders from producing a drug that is essentially a copy of a commercially available FDA-approved product. While a drug sits on the FDA shortage list, that bar is lifted. When the shortage resolves, it snaps back.
Both shortages are over. So routine compounding of tirzepatide is no longer lawful on the basis that created the market — a fact several comparison sites still describe as “permanent legitimacy through 503A/503B.” That claim is simply wrong.
Why every provider suddenly sells “personalized” and “microdose” doses
One narrow route survives. A compounded product is not an “essentially a copy” if the prescriber determines — and documents on the prescription — a significant clinical difference for that individual patient. Changing the strength so it is not “the same, similar, or easily substitutable” for an approved dose is what keeps the product outside the copy definition.
That is the legal mechanism behind the industry-wide pivot to “personalized dosing” and “microdose” programmes. The timing tracks the end of enforcement discretion in early 2025 almost exactly. It is a regulatory workaround, not a clinical innovation, and nobody selling it will tell you so.
The FDA gives examples of a genuine clinical difference — removing an excipient because of a documented allergy, or switching a tablet to a liquid for a patient who cannot swallow — and expressly notes such changes are not necessarily applicable to GLP-1 drugs. That is a pointed signal about how much weight the agency gives this workaround.
Red flags, and what each one tells you
| If you see this… | It means… |
|---|---|
| “FDA-approved compounded tirzepatide” | A false statement. No compounded drug is FDA-approved. Leave. |
| “FDA-approved pharmacy” / “FDA-licensed pharmacy” | Meaningless. Registered ≠ approved. The FDA warns against this phrasing specifically. |
| “Generic Zepbound” / “same as Mounjaro” | False and specifically warned against by the FDA. A compounded drug is not a generic. |
| “Research use only” anywhere on the site | Not for human use. This is the language of the grey market. Leave immediately. |
| No prescription required | Illegal. Tirzepatide is a prescription drug. |
| The pharmacy is never named | You cannot verify the licence, the facility type, or the safety record. That is the point. |
| No salt form or concentration disclosed | The product cannot be assessed on safety at all. |
| “Guaranteed approval” / “guaranteed results” | No clinician can guarantee either. This is a marketing claim, not a medical one. |
A recurring cause is dosing error: patients or clinicians measuring the wrong volume from a multi-dose vial, in documented cases by a factor of ten, some requiring hospitalisation.
This is the clearest concrete safety difference between compounded and brand products, and notably it has nothing to do with the molecule — it is the delivery format. A brand pen or single-dose vial delivers a fixed, pre-measured dose and removes the failure mode entirely. A compounded multi-dose vial reintroduces it. Ask which one you are getting.
The same logic applies to any tirzepatide salt form. A provider that will not state its exact salt form and concentration in writing cannot be evaluated on safety at all — and that refusal is itself the answer to your question.
Adverse events: the figure almost every site gets wrong
Source: FDA GLP-1 webpage, reporting 1,700+ adverse events associated with compounded semaglutide and tirzepatide as of May 21, 2026 — against the 775 total, Feb 2025 figures from February 2025 that almost every comparison site is still quoting. Reports are voluntary and do not establish causation, but the trend is the point.
As of 21 May 2026, the FDA reports having received more than 1,700 adverse events associated with compounded semaglutide and tirzepatide. That is more than double the figure still in circulation, in roughly fifteen months.
Adverse-event reports are voluntary, are not adjudicated, and do not by themselves establish causation. That caveat is real and we will not drop it. But a site that quotes the 2025 number in mid-2026 is not being cautious — it is being out of date, and in a direction that flatters the product it is paid to sell.
This matters far beyond one study, because it exposes the flaw in the whole ‘personalized dosing’ defence. Adding B12 was one of the commonest ways compounders argued their product was not “essentially a copy” of the approved drug — a clinical difference that kept them inside the law. The finding shows that the additive did not merely differentiate the product on paper. It chemically changed it, into something nobody has tested in a human being.
What to do: if you are taking a compounded tirzepatide that contains B12 — and many do, often marketed as ‘tirzepatide + B12’ or ‘with methylcobalamin’ — ask your provider and your pharmacy, in writing, whether they have tested for adduct formation. Most will not have. That answer is itself information.
In the 30 April 2026 Federal Register notice (docket 2026-08552), the agency stated that there is no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk — and went out of its way to clarify that supply and affordability are not what the statute means by clinical need.
In plain terms: there are FDA-approved products; they work; patients can be treated with them. Whether a patient can afford them is a different problem, with a different set of policy tools.
That single sentence does enormous work. Every compounded-GLP-1 marketing page in America is, at bottom, an affordability argument. The agency has now said, on the record, that affordability is not a legal basis for compounding these drugs. If you are choosing a compounded programme because it is cheaper, you should know that the regulator has explicitly said that reason does not count.
The numbers behind this page
What we do not claim in this page
Every price quoted in this page comes from the programme's own pricing page and carries the date it was captured.
We do not claim these prices will hold. Compounded pricing moves within weeks, and a figure without a capture date is not a fact. We do not claim a compounded preparation is equivalent to an approved product: it is not FDA-approved, is not therapeutically equivalent to any brand-name product, and FDA does not review it for safety, effectiveness or manufacturing quality before marketing.
And we do not claim to be a clinical resource. Which molecule suits you, at what dose, and whether treatment is appropriate at all are questions for a prescribing clinician who has your history. This is price research, and it is only useful once those questions are settled.
Reading the price against the market
What the plan term is worth
The figures in this page sit inside a market with a measurable shape, and that shape is what makes any single price readable.
Several programmes publish two prices: the advertised rate, which requires a commitment, and the month-to-month rate, which does not. The gap between them is the price of flexibility, and it is rarely presented that way.
Compounded medication is generally not refundable once shipped, and most discontinuation happens in the first three months — precisely the window a twelve-month prepayment covers. Committing at signup and committing after reaching a dose you tolerate are materially different decisions, even though the advertised rate is identical.
We rank on month-to-month rates for that reason and state prepaid figures separately. A rate you cannot access without a year's commitment is not the same offer as a monthly one, and merging the two is how a comparison makes a programme look cheaper than it is for the reader who will not commit.
What the plan term is worth
The figures in this page sit inside a market with a measurable shape, and that shape is what makes any single price readable.
Several programmes publish two prices: the advertised rate, which requires a commitment, and the month-to-month rate, which does not. The gap between them is the price of flexibility, and it is rarely presented that way.
Compounded medication is generally not refundable once shipped, and most discontinuation happens in the first three months — precisely the window a twelve-month prepayment covers. Committing at signup and committing after reaching a dose you tolerate are materially different decisions, even though the advertised rate is identical.
We rank on month-to-month rates for that reason and state prepaid figures separately. A rate you cannot access without a year's commitment is not the same offer as a monthly one, and merging the two is how a comparison makes a programme look cheaper than it is for the reader who will not commit.
Questions this page answers
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We rank on the month-to-month figure and state the prepaid rate separately, since a rate requiring a year's commitment is not the same offer.
Where do these prices come from?
Each is read from the programme's own published pricing page and carries its capture date. The full set of 24 standard-dose records is at /api/prices.json with molecule and dose class on every record.
What is the cheapest verified GLP-1 programme?
NexLife at $119 a month for semaglutide and $139 for tirzepatide on its 12-month plan, both at standard therapeutic dosing and first-party verified September 4, 2026. Month-to-month, NexLife is $139 and $169; Oak Longevity ($133, flat, no membership) is the next-cheapest semaglutide programme.